[Congressional Record Volume 169, Number 187 (Monday, November 13, 2023)]
[House]
[Page H5673]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
CHARTING NEW COURSE ON NATIONAL DEBT
The SPEAKER pro tempore. The Chair recognizes the gentleman from
Pennsylvania (Mr. Joyce) for 5 minutes.
Mr. JOYCE of Pennsylvania. Mr. Speaker, today, our national debt
stands at over $33 trillion, which is an increase of nearly $5 trillion
since President Joe Biden took office.
By borrowing money from China to subsidize Green New Deal initiatives
like windmills, solar panels, and electric vehicles, President Biden
has failed to rein in spending and sent our national debt soaring to
unprecedented levels.
As Congress looks to address next year's funding, it is clear that a
change needs to be made and that cuts to government waste are needed in
order to right the ship and restore sanity to our budget.
Right now, we are on an unsustainable trajectory that will put making
interest payments on our debt the largest single line item in the
Federal budget, surpassing Social Security, Medicare, and all other
spending programs.
It is time to chart a new course and help return to fiscal solvency
while supporting the priorities that matter the most, priorities like
protecting seniors, funding our military, and securing our border.
Pennsylvania families and, in fact, all American families cannot
afford President Biden's reckless spending, and I call on my colleagues
to join me in working to pass a budget that is responsible and shows
that Congress is working to be solid stewards of American taxpayer
dollars.
Recognizing National Lung Cancer Awareness Month
Mr. JOYCE of Pennsylvania. Mr. Speaker, this November, as we
recognize National Lung Cancer Awareness Month, Congress must look to
find new and innovative solutions to treat this terrible disease. Each
year, lung cancer takes the lives of over 127,000 Americans, more than
any other type of cancer in America.
Unfortunately, at a time when we should be looking for new
innovation, the Inflation Reduction Act, or IRA, has led to a slowdown
in research and development of new drugs and therapies that could be
critical to saving American lives.
New price controls, which were established by the IRA, create a
system of disincentives for smaller, innovative drug manufacturers that
are working to treat rare diseases, including cancer.
To address this issue, I have been joined by a bipartisan group of my
colleagues to introduce the ORPHAN Cures Act. This legislation would
amend the IRA to create a new exemption that would incentivize
researchers to explore the development of new medications to treat rare
diseases and cancers.
The clock is ticking, and now is the time for Congress to pass this
bipartisan solution for our constituents and the patients who are
currently battling cancer and other rare diseases.
____________________